Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
APRE
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.87
vs -19.80
Q3.23
N/A
-0.86
vs -2.40
Q4.23
N/A
-0.92
vs -0.92
Q1.24
N/A
-0.67
vs -1.34
Q2.24
N/A
-0.58
vs -0.87
Q3.24
N/A
-0.64
vs -0.86
Q4.24
N/A
-0.49
vs -0.92
Q1.25
N/A
-0.66
vs -0.67
Q2.25
N/A
-0.71
vs -0.58
Q3.25
N/A
-0.35
vs -0.64
Sales Growth
YoY
Current
Estimates
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
NA
249.7K vs NA
Q3.23
NA
319.5K vs NA
Q4.23
NA
14.1K vs NA
Q1.24
NA
380.6K vs NA
Q2.24
+125%
561.6K vs 249.7K
Q3.24
-100%
NA vs 319.5K
Q4.24
+1362%
205.8K vs 14.1K
Q1.25
-100%
NA vs 380.6K
Return on Equity
QoQ
Q2.23
-14%
-0.14
vs -0.16
Q3.23
-16%
-0.16
vs -0.14
Q4.23
-19%
-0.19
vs -0.16
Q1.24
-9%
-0.09
vs -0.19
Q2.24
-13%
-0.13
vs -0.09
Q3.24
-17%
-0.17
vs -0.13
Q4.24
-15%
-0.15
vs -0.17
Q1.25
-25%
-0.25
vs -0.15
Institutionnal Ownership
QoQ
Q4.22
27
27
vs 25
8%
Q1.23
2
2
vs 27
-93%
Q2.23
1
1
vs 2
-50%
Q3.23
1
1
vs 1
NA
Q4.23
1
1
vs 1
NA
Q1.24
2
2
vs 1
100%
Q2.24
1
1
vs 2
-50%
Q3.24
1
1
vs 1
NA
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
Quote Panel
Key Metrics
Relative Strength
APRE
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
NaN%2026-Revenue
-121%2026-EPS
104%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
Loop Capital Markets
initialisePrevious: Not converted
2023-03-10
Now: Buy
Citigroup
initialisePrevious: Not converted
2023-03-10
Now: Buy
RBC Capital
initialisePrevious: Not converted
2023-03-10
Now: Outperform
Cowen & Co.
initialisePrevious: Not converted
2023-03-10
Now: Market Perform
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
NASDAQ
Unprofitable
Unprofitable
-0.15 ( -8.57%)
After-hours 1.52$-0.08 (-5.00%)
Relative Strenght
4
Volume Buzz
-35%
Earning Acce
No
Dist 52w H.
70%